SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Achaogen, a biopharmaceutical company discovering and developing antibiotics to treat life-threatening, multi-drug resistant (MDR) bacterial infections, today announced key upcoming data presentations involving its lead antibiotic candidate ACHN-490. The data are being presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Boston from September 12th through September 15th, 2010.
